Clough Capital Partners L P Makes New $1.92 Million Investment in Krystal Biotech, Inc. $KRYS

Clough Capital Partners L P purchased a new position in Krystal Biotech, Inc. (NASDAQ:KRYS) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 7,806 shares of the company’s stock, valued at approximately $1,924,000.

Several other hedge funds have also recently modified their holdings of the business. Avoro Capital Advisors LLC raised its stake in shares of Krystal Biotech by 4.0% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,888,888 shares of the company’s stock worth $712,226,000 after purchasing an additional 111,111 shares during the last quarter. State Street Corp raised its stake in shares of Krystal Biotech by 10.5% in the second quarter. State Street Corp now owns 1,355,346 shares of the company’s stock worth $186,306,000 after purchasing an additional 128,639 shares during the last quarter. Soleus Capital Management L.P. raised its stake in shares of Krystal Biotech by 108.9% in the second quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock worth $126,870,000 after purchasing an additional 481,200 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Krystal Biotech by 5.5% in the third quarter. Dimensional Fund Advisors LP now owns 533,964 shares of the company’s stock worth $94,261,000 after purchasing an additional 28,075 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its stake in shares of Krystal Biotech by 13.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 529,955 shares of the company’s stock worth $130,656,000 after purchasing an additional 62,897 shares during the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Stock Performance

Krystal Biotech stock opened at $341.66 on Thursday. The stock has a market cap of $10.07 billion, a PE ratio of 45.68 and a beta of 0.53. Krystal Biotech, Inc. has a one year low of $127.99 and a one year high of $347.67. The stock has a fifty day moving average of $292.56 and a 200 day moving average of $270.63.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, May 4th. The company reported $1.83 EPS for the quarter, beating analysts’ consensus estimates of $1.45 by $0.38. The company had revenue of $116.36 million during the quarter, compared to analysts’ expectations of $112.11 million. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%. As a group, sell-side analysts predict that Krystal Biotech, Inc. will post 7.83 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. Chardan Capital boosted their price target on Krystal Biotech from $220.00 to $323.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. Evercore restated an “outperform” rating and issued a $300.00 price target on shares of Krystal Biotech in a research note on Tuesday, May 5th. Guggenheim boosted their price target on Krystal Biotech from $224.00 to $284.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Citigroup boosted their price target on Krystal Biotech from $371.00 to $378.00 and gave the stock a “buy” rating in a research note on Tuesday, May 5th. Finally, Weiss Ratings upgraded Krystal Biotech from a “buy (b-)” rating to a “buy (b)” rating in a research note on Tuesday. Ten research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $329.78.

Insiders Place Their Bets

In related news, EVP John Charles Thomas sold 642 shares of the company’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $302.03, for a total transaction of $193,903.26. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $308.11, for a total value of $7,702,750.00. Following the sale, the insider owned 1,378,155 shares of the company’s stock, valued at approximately $424,623,337.05. This trade represents a 1.78% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.10% of the stock is currently owned by corporate insiders.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.